Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic therapy with talaporfin sodium (ME2906) and PNL6405CIN for cervical intraepithelial neoplasia and effects on vaginal bacteria
jRCTs041230002Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Apr 2023
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of talaporfin sodium in cervical intraepithelial neoplasia (CIN), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Change in vaginal bacterial cultures. Started Apr 2023; status: completed.
02
Drugs
talaporfin sodium
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on jRCTs041230002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230002.